Mo1030 Efficacy of Antiviral Therapy in Reactivation Prophylaxis in Patients With Hepatitis B (HBV) Infection Treated With Different Immunosuppressive Agents

Abstract

A S L D A b st ra ct s diagnosed with chronic hepatitis B (ICD-9-CM codes 070.2 and 070.3) at our institution during 2011-2014. In addition to patient demographics, characteristics of chronic hepatitis B and treatment patterns were examined. The chi-square test and multivariate logistic model were used in statistical analysis. Results: Our study sample of 111 chronic hepatitis B patients included 66 Asians, 18 African Americans, and 27 other races, with mean age of 46.7 (standard deviation 12.6), 61.3% female, 2.7% with family history of HCC, and 3.6% cirrhotic. Eighteen patients (16.2%) reported at least occasional alcohol use and 49 patients (44.1%) were treated with an anti-HBV medication, mainly tenofovir (n=36) followed by entecavir (n=9). Fifty two patients (46.8%) were deemed at high risk for HCC per the AASLD guideline, of which 51 patients (98.1%) underwent or were recommended to undergo an imaging study (ultrasound, CT or MRI) at their most recent visit. Use of anti-HBV medication was positively associated with age and cirrhosis (both p<0.05) but not family history of HCC, AASLD high-risk status, or other variables. In multivariate logistic regression, age was the only significant predicator of anti-HBV medication use (odds ratio 1.03, 95% confidence interval 1.002 1.07). Conclusions: The majority of chronic hepatitis B patients deemed at high risk for HCC underwent or were recommended to undergo imaging study. Interestingly, such high-risk status for HCC was not associated with a higher likelihood of anti-HBV treatment. Whether recent introduction of generic entecavir will lead to more antiHBV treatment is an important question for future research.